Clinical data | |
---|---|
Other names | 2-indanylamine; 2-indanamine |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.019.111 ![]() |
Chemical and physical data | |
Formula | C9H11N |
Molar mass | 133.194 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
2-Aminoindane (2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug.[1] It acts as a selective substrate for NET and DAT.[2][3]
Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters.[4] 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat discrimination tests.[5]
Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.[6]
There are a number of derivatives of 2-aminoindane and its positional isomer 1-aminoindane exist, including:
As of October 2015 2-AI is a controlled substance in China.[7]
2-Aminoindane is not scheduled at the federal level in the United States,[8] but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.